The clinical course and response to therapy of patients with immune thrombocytopenic purpura (ITP) are not completely determined by the level of IgG present on the platelet surface. It is possible that antibodies of other immunoglobulin classes also play a role in platelet destruction in some of these patients. Therefore, we studied 175 patients with ITP for the presence of IgM anti-platelet antibodies using radiolabeled polyclonal or monoclonal anti-IgM. We observed that 57% of patients with clinical ITP had increased levels of IgM on their platelets, compared with normal controls and patients with thrombocytopenia who did not have ITP (<10%), (P < 0.01). We obtained similar results using either radiolabeled polyclonal or monoclonal anti-IgM, reagents whose integrity was first characterized using erythrocytes coated with defined amounts of IgM antibody. Among patients with increased platelet-IgM there was a significant correlation both with the presence of increased platelet-C3 as well as the amount of platelet-C3 (P < 0.01, r = 0.53). We demonstrated the presence of warm-reacting IgM antiplatelet antibodies in the plasma of two of these patients who were further studied. The isolated IgM fraction from these two plasmas was able to activate complement and place 3H-C3 on normal platelets. These studies demonstrate the presence of warm-reacting IgM anti-platelet antibodies in some patients with ITP. They suggest that the binding of complement to platelets by IgM antibodies may initiate platelet clearance as well as enhance the effect of IgG antibodies in ITP.
Introduction
Thrombocytopenia in patients with immune thrombocytopenic purpura (ITP)' is caused by the accelerated removal of immunoglobulin-coated platelets from the circulation. The most important ligand on the platelet surface recognized by tissue macrophages is IgG, either in the form of antibody or immune complexes. It is less clear, however, whether the measured amount of IgG on the platelet surface, by itself, determines either the extent of the platelet destruction or the magnitude of the thrombocytopenia (1) (2) (3) (4) (5) (6) . For example, increased amounts of platelet-bound IgG have been detected in some patients whose thrombocytopenia is not believed to be mediated by antiplatelet antibodies (7) (8) (9) (10) . Furthermore, increased plateletIgG is detected in occasional patients who have a normal platelet count (7, 8) . These data suggest that factors other than the amount of IgG on the platelet influence the recognition and removal of ITP platelets.
One such factor that might accelerate platelet clearance is C3, the third component of complement. In patients with immune hemolytic anemia, for example, the presence of cellbound C3 influences the rate and site of erythrocyte clearance (l1). Several investigators have noted increased amounts of C3 on the platelets of some patients with ITP. This increase in platelet-C3 is generally associated with the presence of increased amounts of platelet-IgG (12) (13) (14) (15) . However, we have observed that some ITP patients have increased levels of platelet-associated (PA)-C3 with normal levels of PA-IgG (13). In these cases, the deposition of C3 could result from the presence of anti-platelet antibodies of the IgM class that are known to activate complement more efficiently than most IgG antibodies. Indeed, several investigators have recently observed increased amounts of IgM on the platelets of some patients with ITP (15) (16) (17) (18) (19) (20) (21) (22) . Therefore, we sought to determine if complement-fixing IgM anti-platelet antibodies are, in fact, demonstrable in ITP and could account for the presence of C3 on the platelets of some of these patients. We also sought to determine whether the presence of IgM antibody might help to explain some of the variation in the severity of ITP.
Methods
Patients. We initially studied 127 consecutive patients with idiopathic thrombocytopenic purpura using previously reported criteria for diagnosis (13). Platelet counts in these patients ranged from 5,000 to 258,000/mm3 (96,000±77,000/mm3, mean±2 SD). 104 patients were thrombocytopenic (platelet count < 150,000/mm3) while 23 were in clinical remission at the time of study. 99 patients were untreated, while 28 were taking corticosteroids, eight had undergone splenectomy, two were receiving intraveneous gammaglobulin, and one was receiving infusions of vinblastine. We also studied the platelets obtained from 78 normal healthy volunteers and 32 thrombocytopenic patients who did not have a clinical diagnosis of ITP. The causes of thrombocytopenia in these patients included hypersplenism (3) , marrow suppression from chemotherapy (1), drug-induced thrombocytopenia (6) , hereditary thrombocytopenia (2) , chronic lymphocytic leukemia (3), marrow involvement with another malignant (5) or a nonmalignant process (4), marrow hypoplasia (4) , disseminated intravascular coagulation (3), and sepsis (1) . The We determined the level of platelet-bound IgG, IgM, and C3 as well as plasma IgG and IgM anti-platelet antibody activity using the radiolabeled antiglobulin test (13). In this assay, the level of plateletbound immunoglobulin or C3 is determined by the extent of binding ofthe specific radiolabeled antiglobulin reagent. Briefly, I X 108 washed platelets from patients or normal donors were incubated with an aliquot of each labeled ligand for 45 min at 370C, washed four times, and the platelet-bound radioactivity determined. In the indirect test, I X 108 washed normal platelets were first incubated with normal or patient plasma in 0.01 M EDTA buffer, washed four times, and then incubated with each labeled ligand. Assays on patient platelets were generally performed using 1 sg of each heterologous antibody, monoclonal anti-a chain antibody, or similarly labeled normal rabbit IgG, per 108 platelets. Specific binding of rabbit IgG anti-IgM to platelets (i.e., that portion of total binding due solely to the interaction of the anti-IgM antibody with platelet-bound IgM) was first assessed by preincubating platelets with a 100-fold excess of normal rabbit IgG before incubation with '25I-IgG anti-IgM. In addition, we compared the binding to platelets of labeled IgG anti-IgM and labeled normal rabbit IgG not having antibody activity. In experiments in which we measured the binding of monoclonal IgG anti-IgM to platelets, we used the radiolabeled IgG fraction of the parent mouse myeloma line (P3) as the nonimmune control. Binding of`25I-P3 to all platelets was <0.05% of the total available radioactivity in all experiments. The extent of binding of each antiglobulin preparation to platelets is expressed as a percentage of the total radioactivity to which the platelet was exposed according to the formula: % binding = (platelet-associated cpm -test tube cpm)/(total cpm -test tube cpm) X 100.
Binding of`25I anti-IgM to antibody-coated erythrocytes. We first determined the optimal conditions for detecting cell-bound IgM by studying the binding of '251 anti-IgM to IgM-coated erythrocytes. The IgM fraction of anti-erythrocyte blood group A substance was prepared from human antiserum by gel filtration chromatography (13) and quantitated as protein (24) . We then radiolabeled the IgM preparation with tritium using N-succinimidyl (2,3-3H) . In parallel studies we also determined the extent of crossreactivity of "25I anti-IgM with cell-bound IgG by measuring its binding to type A erythrocytes that were sensitized with equivalent amounts of 3H-IgG and 3H-IgM anti-A. In order to quantitate the amount of labeled anti-IgM that binds to cell-bound IgM at saturation, type A blood cells that were sensitized with a single concentration of 3H-IgM anti-A were then incubated with varying concentrations of 1251 antiIgM and the cell-associated radioactivity determined. We also compared the binding of the labeled polyclonal and monoclonal anti-IgM reagents to erythrocytes that were sensitized with varying concentrations of 3H-IgM anti-A.
Preparation of human C3. C3 was isolated from human plasma by the method of Hammer et al. (26) with slight modifications. A 1,200-ml pool of fresh frozen plasma was obtained from two donors (Community Blood Bank, Philadelphia, PA) treated with 50 mM epsilonaminocaproic acid and I mM phenylmethanesulfonyl fluoride, and precipitated with 5% polyethylene glycol. The supernatant was applied to a Sepharose L-lysine column to remove plasminogen. 500 ml of this plasminogen-free plasma was dialyzed and fractionated on a DEAE Sephacel column (5 X 100 cm) using a linear salt gradient (1.3-10.5 mmho conductivity). Fractions were analyzed for complement and immunoglobulin proteins by effective molecule titration and Ouchterlony analysis. Trace amounts of IgG, IgA, and C5 were removed by hydroxylapatite chromatography as assessed by Ouchterlony analysis and effective molecule titration of C5. The concentration of the purified C3 was 1.25 mg/ml by radial immunodiffusion and 16,000 hemolytically effective units per milliliter by effective molecule titration. This is similar to the data we observed for the C3 in normal plasma before isolation where C3 (I mg/ml) had a specific hemolytic activity of 10,000 effective units per milliliter. The resultant protein was analyzed using SDS-7.5% polyacrylamide disc gels which were then stained for protein with Coomassie Blue. The C3 preparation consisted of a single protein band with an apparent molecular weight of 230,000, which produced the characteristic a-and ,-chains upon reduction in 2-mercaptoethanol. The eluted protein from alkaline disc gels run in parallel was shown to be C3 by Ouchterlony analysis.
The purified C3 was then radiolabeled with 3H using NSP as above. After radiolabeling, unbound NSP was separated from 3H-C3 using Sephadex G-50. The labeled C3 had a specific activity of -1.0 X 10I cpm/Mg C3 and retained 85-95% of its initial hemolytic activity when assayed by effective molecule titration (11, 27 Binding of 25I polyclonal anti-IgM to human platelets. We then studied the binding of radiolabeled anti-IgM to platelets from normal donors and patients with thrombocytopenia. When washed platelets obtained from each of 78 normal individuals were incubated with 125I-polyclonal IgG anti-IgM, 0.09±0.14% (mean±2 SD) of the available radioactivity bound to the cells (Table I, Fig. 7) . In contrast, when the same number of normal platelets were incubated with an identical amount of '251-normal rabbit IgG that did not have antiimmunoglobulin activity, 0.04±0.04% (mean±2 SD) of the available radioactivity bound to the cells (Table I ). This suggested that approximately half of the total binding of the labeled anti-IgM to normal platelets is specific for plateletbound IgM. Similarly, when washed normal platelets were preincubated with a 100-fold excess of unlabeled normal rabbit Fig. 3 ).
We then studied the binding of 1251 anti-IgM to platelets obtained from 127 patients who had a clinical diagnosis of ITP (Table I, Fig. 7 ). The platelets of these patients bound 0.28±0.41% (mean±2 SD) of the total available radioactivity (Table I, Fig. 7 ). The platelets from 66 of these 127 patients (52%) showed an increase in the binding of 1251 anti-IgM, which was >2 SD from the mean value of the normal population; platelets from 43 patients bound anti-IgM in excess of 3 SD from the mean. In contrast, the binding of normal rabbit IgG by ITP platelets was essentially identical to its binding by normal platelets (Table I) . We also studied the platelets from two patients with Waldenstrom's macroglobulinemia who had serum concentrations of IgM of 2.5 and 2.8 g/dl and who had platelet counts of 80,000/mm3 and 120,000/ mm3, respectively. In both cases, platelet-IgM fell within the normal range. Platelets from only 4 of 32 patients with thrombocytopenia, who did not have a clinical diagnosis of ITP, bound increased amounts of anti-IgM (Fig. 7 , Table I ). Two of these four had demonstrable drug-dependent (gold, Fig. 9 ). However, platelets from 5 ITP patients which bound significantly increased amounts of polyclonal anti-IgM bound amounts of monoclonal anti-IgM which clearly fell within the normal range. In two cases, we noted a borderline elevation in the binding of the monoclonal reagent that was associated with a normal level of binding of polyclonal anti-IgM (Fig. 9) .
Presence of IgM anti-platelet antibodies in ITP plasma.
These findings suggest that increased amounts of IgM are often present on ITP platelets. The data also suggest that IgM antiplatelet antibody may initiate binding of C3 to the platelet surface. We, therefore, sought to determine directly if warmreacting IgM anti-platelet antibodies were present in the plasma of some patients with ITP and whether they activated complement.
We studied the plasmas from four patients with ITP who had increased levels of platelet-associated IgM. The plasmas from two of these four patients placed increased amounts of IgM onto normal platelets (1.28 and 1.43% binding of 125I anti-IgM) when compared with normal plasma (0.40±0.38% binding of 125I anti-IgM) (mean±2 SD, n = 53). These two patient plasmas and the IgM fractions isolated from them also caused C3 consumption, as assessed by effective molecule titration (not shown), and the deposition of 3H-C3 onto the platelet surface (Table IV) isolated from a patient with anti-PI"A antibody also caused platelet C3 deposition as previously reported (27).
Discussion
It is generally accepted that the platelets from most patients with ITP have increased levels of IgG on their surface. The platelets of Some ITP patients have increased levels of C3 as well. Several investigators have observed that the platelets from a subset of ITP patients have increased C3 on their surface without a detectable increase in IgG. Since this increased C3 on the platelet surface may have been caused by complement activation initiated by another class of antibody, we examined the level of PA-IgM on ITP platelets.
We first established the integrity of our radiolabeled IgG anti-IgM antibody using human erythrocytes that were quantitatively coated with 3H-IgM anti-A. We found that we could detect the binding of labeled anti-IgM to as few as 50 IgM anti-A molecules on the surface of the erythrocyte, and that (Fig. 9) . The reason for this result is uncertain. Allotypic restriction has been described among autoantibodies in autoimmune hemolytic anemia and other disorders (33) . It is not known whether there are similar antigenic restrictions among autoreactive antiplatelet antibodies and if the epitope recognized by some monoclonal anti-IgM antibodies is uniformly present on all IgM anti-platelet antibodies.
In this entire series, increased PA-IgM was found on the platelets of only 4 of 44 thrombocytopenic patients who did not have ITP; in two patients, drug-dependent thrombocytopenia was suspected which, in fact, may have been mediated by anti-platelet antibody. Therefore, the finding of increased amounts of platelet-bound IgM on ITP platelets in this study appears to be a less sensitive, but a more specific serologic marker for ITP than is the finding of increased platelet-IgG (Fig. 7) (20) . Additional study will be required to identify the antigen(s) recognized by these antibodies.
Finally, we asked whether the presence of IgM antibody was more likely to occur in certain clinically distinct subgroups of patients with ITP or whether PA-IgM played a role in the clinical course and management of this disease. It is possible, for example, that IgM antibodies directly injure platelets, and lead to their removal by nonimmunologic mechanisms. In agreement with other groups of investigators, we found a complex immunologic profile on ITP platelets (Table II) . However, we did not observe a relationship between the level of PA-IgM, as an independent variable, and the platelet count. In part, this may relate to the heterogeneous population studied, which included adults and children, acute and chronic ITP, and both newly diagnosed and heavily treated patients. In part, this may also reflect the fact that the platelet count is a dynamic value that is dependent upon antibody titer and class, efficiency of clearance by the phagocytic system, and extent of marrow production. Binding of C3 to erythrocytes, initiated by IgM antibodies, plays a major role in the site and rate of removal of these cells from the circulation. However, a larger prospective study of a more homogeneous patient population will be needed to determine whether the presence of IgM and C3 on platelets is an important determinant of platelet count, platelet function, site of sequestration, or response to therapy in ITP.
